BIOCYTOGEN-B News

Baiaosetu (2315.HK) 2023 review: Overseas revenue is growing rapidly, Qianmu Wanbang has completed phased R&D, and the self-research pipeline is successfully authorized and transferred to the outside world

Apr 3 00:00

BIOCYTOGEN(2315.HK):REDUCING BURN RATE WITH STRONG INCOME GROWTH AND BETTER OPERATING EFFICIENCY

招银国际Aug 29, 2023 20:22

Biosetu (2315.HK) 2022 Performance Review: Overseas Growth Accelerates, Pushes Back Smoothly, Plans to Return to the Science and Technology Innovation Board

海通國際Mar 31, 2023 14:36

Biosettu-B (02315.HK): Business blossomed more and maintained rapid growth

東吳證券Mar 29, 2023 12:58

CMB International: Maintains target price of HK$37.96 for the “Buy” rating for Baiyosetu-B (02315)

Zhitong FinanceMar 29, 2023 10:40

First coverage by Baioxetu (2315.HK): Preclinical CRO high gross profit growth, thousands of mice, millions of anti-stars, ocean, all-round enabling antibody drug development circuit

海通國際Dec 7, 2022 13:11

BioOlympics-B (02315.HK): Technological Innovation Builds High Barriers, Diversified Businesses, Open Up Wide Spaces

東吳證券Sep 13, 2022 20:11

Biosetu Pharmaceutical Technology (2315.HK) IPO Report

中泰國際Aug 19, 2022 00:00

BioSeto (2315.HK) Review: Antibody Development and Preclinical Research Service Company Relying on a Whole-Human Mouse Technology Platform

安信國際Aug 19, 2022 00:00